Sun Pharmaceutical Industries Ltd. has reported a significant shift in its business mix, with innovative medicines outpacing generic drug sales in the United States during the second quarter of fiscal year 2026. The company’s innovative medicines, including Ilumya, Cequa, and Odomzo, drove strong demand and growth. The recent launch of Leqselvi, a newly approved alopecia treatment, has further accelerated this growth. Leqselvi was acquired through Sun Pharma’s $576 million purchase of Concert Pharma and has been well received in the US market.
The company’s global innovative drug revenue reached $333 million in Q2FY26, up 16.4% year-over-year, accounting for 20.2% of total consolidated revenue. For the first half of FY26, innovative drug sales totaled $644 million, growing 16.6% year-over-year. Sun Pharma’s CEO, Richard Ascroft, noted that sales of innovative medicines will continue to rise as the company prepares to launch its cancer immunotherapy, Unloxcyt.
The company’s executive chairman, Dilip Shanghvi, reaffirmed the company’s focus on expanding its R&D pipeline and is awaiting updated FDA labeling approval for Unloxcyt ahead of its planned US launch in the second half of FY26. This shift towards innovative and specialty medicines is expected to strengthen the company’s margins and enhance market differentiation, securing long-term growth in the US and global pharmaceutical markets.
Sun Pharma’s strategic move towards innovative medicines is a significant development, as it positions the company for sustained growth and profitability. The company’s investment in R&D and its pipeline of new products, including Unloxcyt, are expected to drive future growth. With the pharmaceutical industry increasingly shifting towards innovative and specialty medicines, Sun Pharma’s strategy is well-aligned with industry trends. Overall, the company’s Q2FY26 results indicate a positive outlook for its innovative medicines business, and investors will be watching the company’s progress closely in the coming quarters.